In a 54-year-old woman with chronic migraine refractory to sumatriptan, rimegepant, and naproxen, who responds only to ubrogepant (Ubrelvy) but lacks insurance coverage and experiences daily headaches alongside cervical disc disease, what management options are recommended?

{
  "question": "A patient with chronic migraine refractory to sumatriptan, rimegepant, and naproxen, who responds only to ubrogepant (Ubrelvy) but lacks insurance coverage and experiences daily headaches alongside cervical disc disease, what management options are recommended?"
}

Management of Daily Headaches in a Patient Requiring Ubrogepant Without Insurance Coverage

This patient requires immediate initiation of migraine preventive therapy to reduce daily headache frequency and medication overuse, while simultaneously addressing insurance barriers for ubrogepant access.

Critical Assessment: Medication Overuse Headache

The daily headache pattern strongly suggests medication-overuse headache (MOH), which must be addressed before any treatment can be effective. When patients use acute migraine medications (including triptans and gepants like ubrogepant) more than twice weekly, they risk developing rebound headaches that perpetuate the cycle 1. The guidelines explicitly warn that narcotic use should be avoided for chronic daily headaches because it leads to dependency, rebound headaches, and eventual loss of efficacy 1.

Key principle: Even ubrogepant, though effective for this patient, cannot work optimally when used daily. The patient needs preventive therapy, not more frequent acute treatment 2.

Immediate Management Strategy

Step 1: Initiate Preventive Therapy NOW

Start migraine prevention immediately—this is the only way to break the daily headache cycle. The 2003 AAFP/ACP-ASIM guidelines clearly state that preventive therapy is indicated when patients have two or more migraine attacks per month producing disability for three or more days, or when rescue medication is used more than twice weekly 2. This patient meets all criteria.

Preventive options to consider:

• Topiramate or onabotulinumtoxinA have the strongest evidence for chronic migraine prevention 3
• OnabotulinumtoxinA is FDA-approved specifically for chronic migraine (≥15 headache days/month) 3
• Beta-blockers, tricyclic antidepressants, or anticonvulsants as alternatives 2

The 2024 VA/DoD guideline emphasizes that preventive therapy should be assessed after 2-3 months for oral medications and 6-9 months for onabotulinumtoxinA 4.

Step 2: Address Ubrogepant Access While Limiting Use

Continue pursuing prior authorization aggressively, but educate the patient that ubrogepant must be limited to ≤2 days per week maximum 2. The guidelines are explicit: to guard against medication-overuse headaches, acute treatment should be limited to no more than twice weekly 2.

Insurance strategy:

• Document all failed therapies (sumatriptan, rimegepant, naproxen) in detail
• Emphasize that ubrogepant is the only effective acute medication
• Request samples or manufacturer assistance programs while awaiting approval
• Consider patient assistance programs directly from the manufacturer

Step 3: Bridge Therapy for Acute Headaches

While establishing preventive therapy and limiting ubrogepant use, consider alternative acute treatments that haven't been tried:

First-line options to trial 1:

• Aspirin-acetaminophen-caffeine combination (strong recommendation, NNT=4 for pain relief at 2 hours) 4
• Ibuprofen 400-800 mg (if not already tried adequately) 1
• Ketorolac (Toradol) IM for severe breakthrough migraines (relatively rapid onset, rebound unlikely) 1

Second-line options 1:

• Alternative triptans (rizatriptan, zolmitriptan, naratriptan)—the guidelines emphasize that if one triptan fails, a different triptan should be tried 1
• Dihydroergotamine (DHE) nasal spray or parenteral for severe migraines 1

Adjunctive therapy for nausea 1:

• Metoclopramide or prochlorperazine (which can also relieve headache pain) 1

Step 4: Address Cervicogenic Component

The cervical disc disease may be contributing to a mixed headache picture. Consider:

• Greater occipital nerve blockade (weak recommendation for acute migraine treatment) 4
• Physical therapy focused on cervical spine
• Ensure cervical pain management is optimized separately

Critical Pitfalls to Avoid

1. Do NOT prescribe opioids or butalbital-containing compounds—these worsen chronic daily headaches through dependency and rebound 1

2. Do NOT continue daily ubrogepant use even if insurance approves—this perpetuates medication overuse 2

3. Do NOT delay preventive therapy—waiting for insurance approval while the patient suffers daily headaches is inappropriate management 2

4. Do NOT abandon the treatment plan if preventive therapy doesn't work immediately—efficacy takes 2-3 months for oral medications 4, 5

Neurology Referral

The neurology referral is appropriate and should proceed, but the primary care provider must initiate preventive therapy now rather than waiting. The neurologist can optimize and adjust the regimen, but delaying treatment worsens outcomes.

Expected Timeline

• Weeks 1-4: Initiate preventive therapy, limit ubrogepant to ≤2 days/week, trial alternative acute medications
• Months 2-3: Assess preventive therapy efficacy, adjust dose or switch if needed
• Month 3+: If preventive therapy reduces headache frequency to ≤8 days/month, ubrogepant can be used more effectively for breakthrough migraines

The goal is to reduce monthly headache days by ≥50%, which will make the limited ubrogepant supply adequate for true breakthrough migraines 5.